BEAT-AML trial provides proof of principle for a precision medicine for pts aged >60 yrs with AML: 95% has molecular profiling completed within 7 days and 30-day mortality was lower in the 57% of pts who received targeted therapy (3.7% vs 20.4% with SOC)

Part 2 of an awesome week of great collaborative studies coming out; the Beat AML Master Trial! An amazing effort led by Amy Burd @LLSResearch , John Byrd @OSUCCC_James , Brian Druker @OHSUNews and myself @sloankettering.

Online now @NatureMedicine – Treatment of #leukemia patients based on genomic profiling is feasible and improves patients' outcomes. Initial results from the Beat AML umbrella #Clinicaltrial 👉🏾nature.com/articles/s4159… #precisionmedicine pic.twitter.com/gLonvEQkaA

Results from a study published in @NatureMedicine by Winship investigators William Blum, MD, Martha Arellano, MD, and colleagues show that older patients with AML can benefit from using genetic information to match patients to targeted therapies. #leusm

#PrecisionMedicine Tx in AML using prospective genomic profiling: feasibility & preliminary efficacy of the Beat AML Master Trial [Oct 26, 2020] Burd @rosslevinemd et al. @NatureMedicine ow.ly/70vc50C41sN #AMLsm #leusm #NCT03013998 n=395 >=60yo 1L AML. Improved OS

This report in Nature Medicine, summarizes up-to-date findings of Beat AML, a trial incorporating genomic data into treatment decisions. Overall survival was significantly longer in patients matched to treatments than those receiving SOC.

#PrecisionMedicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial [Oct 26, 2020] Amy Burd @rosslevinemd et al @NatureMedicine ow.ly/70vc50C41sN #AMLsm #leusm #NCT03013998